Interferon Gamma Release Assay and Tuberculin Skin Test Performance in Pregnant Women Living With and Without HIV.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
14
05
2021
accepted:
27
09
2021
pubmed:
12
10
2021
medline:
8
3
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
HIV and pregnancy may affect latent TB infection (LTBI) diagnostics. Tuberculin skin test (TST) and newer generation QuantiFERON-TB Gold Plus (QFT-Plus) evaluations in pregnant women living with HIV (WLHIV) and without HIV are lacking. In this cross-sectional study, pregnant women underwent TST and QFT-Plus testing during antenatal care in Kenya. We estimated LTBI prevalence and TST and QFT-Plus performances. Diagnostic agreement was assessed with kappa statistic, participant characteristics associated with LTBI and HIV were assessed with generalized linear models, and QFT-Plus quantitative responses were assessed with Mann-Whitney U test. We enrolled 400 pregnant women (200 WLHIV/200 HIV-negative women) at median 28 weeks gestation (interquartile range 24-30). Among WLHIV (all on antiretroviral therapy), the median CD4 count was 464 cells/mm3 (interquartile range 325-654); 62.5% (125) had received isoniazid preventive therapy. LTBI prevalence was 35.8% and similar among WLHIV and HIV-negative women. QFT-Plus testing identified 3-fold more women with LTBI when compared with TST (32% vs. 12%, P < 0.0001). QFT-Plus positivity prevalence was similar regardless of HIV status, although TB-specific antigen responses were lower in WLHIV than in HIV-negative women with LTBI (median QFT-TB1 1.05 vs. 2.65 IU/mL, P = 0.035; QFT-TB2 1.26 vs. 2.56 IU/mL, P = 0.027). TST positivity was more frequent among WLHIV than among HIV-negative women (18.5% vs 4.6%; P < 0.0001). QFT-Plus assay had higher diagnostic yield than TST for LTBI in WLHIV and HIV-negative women despite lower TB-specific antigen responses in WLHIV. Higher TST positivity was observed in WLHIV. LTBI diagnostic performance in the context of pregnancy and HIV has implications for clinical use and prevention studies, which rely on these diagnostics for TB infection entry criteria or outcomes.
Sections du résumé
BACKGROUND
HIV and pregnancy may affect latent TB infection (LTBI) diagnostics. Tuberculin skin test (TST) and newer generation QuantiFERON-TB Gold Plus (QFT-Plus) evaluations in pregnant women living with HIV (WLHIV) and without HIV are lacking.
METHODS
In this cross-sectional study, pregnant women underwent TST and QFT-Plus testing during antenatal care in Kenya. We estimated LTBI prevalence and TST and QFT-Plus performances. Diagnostic agreement was assessed with kappa statistic, participant characteristics associated with LTBI and HIV were assessed with generalized linear models, and QFT-Plus quantitative responses were assessed with Mann-Whitney U test.
RESULTS
We enrolled 400 pregnant women (200 WLHIV/200 HIV-negative women) at median 28 weeks gestation (interquartile range 24-30). Among WLHIV (all on antiretroviral therapy), the median CD4 count was 464 cells/mm3 (interquartile range 325-654); 62.5% (125) had received isoniazid preventive therapy. LTBI prevalence was 35.8% and similar among WLHIV and HIV-negative women. QFT-Plus testing identified 3-fold more women with LTBI when compared with TST (32% vs. 12%, P < 0.0001). QFT-Plus positivity prevalence was similar regardless of HIV status, although TB-specific antigen responses were lower in WLHIV than in HIV-negative women with LTBI (median QFT-TB1 1.05 vs. 2.65 IU/mL, P = 0.035; QFT-TB2 1.26 vs. 2.56 IU/mL, P = 0.027). TST positivity was more frequent among WLHIV than among HIV-negative women (18.5% vs 4.6%; P < 0.0001).
CONCLUSIONS
QFT-Plus assay had higher diagnostic yield than TST for LTBI in WLHIV and HIV-negative women despite lower TB-specific antigen responses in WLHIV. Higher TST positivity was observed in WLHIV. LTBI diagnostic performance in the context of pregnancy and HIV has implications for clinical use and prevention studies, which rely on these diagnostics for TB infection entry criteria or outcomes.
Identifiants
pubmed: 34629414
doi: 10.1097/QAI.0000000000002827
pii: 00126334-202201010-00013
pmc: PMC8665065
mid: NIHMS1745608
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-107Subventions
Organisme : NICHD NIH HHS
ID : R21 HD098746
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI120793
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI142647
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Sobhy S, Babiker Z, Zamora J, et al. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic Review and meta-analysis. BJOG. 2017;124:727–733.
Sugarman J, Colvin C, Moran AC, et al. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health. 2014;2:e710–e716.
Zumla A, Bates M, Mwaba P. The neglected global burden of tuberculosis in pregnancy. Lancet Glob Health. 2014;2:e675–e676.
Salazar-Austin N, Hoffmann J, Cohn S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: the tshepiso study. Clin Infect Dis. 2018;66:921–929.
Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and Research gaps, Clin Infect Dis 2012:55:1532–1549.
Lawn SD, Wood R, Wilkinson RJ. Changing concepts of “latent tuberculosis infection” in patients living with HIV infection. Clin Dev Immunol. 2011;2011:980594.
Zenner D, Kruijshaar ME, Andrews N, et al. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185:779–784.
Mathad JS, Bhosale R, Sangar V, et al. Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high-burden setting. PloS one. 2014;9:e92308.
Mathad JS, Bhosale R, Balasubramanian U, et al. Quantitative ifn-gamma and il-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016;193:1421–1428.
Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic Review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56:230–238.
Konig Walles J, Tesfaye F, Jansson M, et al. Performance of quantiferon-Tb Gold plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. PLoS One. 2018;13:e0193589.
Birku M, Desalegn G, Kassa G, et al. Effect of pregnancy and hiv infection on detection of latent TB infection by tuberculin skin test and quantiferon-TB Gold in-tube Assay among women living in a high TB and HIV burden setting. Int J Infect Dis. 2020;101:235–242.
Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372:2127–2135.
Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3–20.
Qiagen. Quantiferon®-Tb Gold Plus (Qft®-Plus) Elisa Package Insert. Available at: http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf . Accessed October 26, 2020.
Rozot V, Patrizia A, Vigano S, et al. Combined use of Mycobacterium tuberculosis-specific Cd4 and Cd8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infect Dis. 2015:60:432–437.
LaCourse SM, Cranmer LM, Matemo D, et al. Effect of pregnancy on Interferon gamma release assay and tuberculin skin test detection of latent TB infection among HIV-infected women in a high burden setting. J Acquir Immune Defic Syndr. 2017;75:128–136.
Weinberg A, Aaron L, Montepiedra G, et al. Effects of pregnancy and isoniazid preventive therapy on mycobacterium tuberculosis interferon gamma response assays in women with HIV. Clinical Infect Dis. 2020:1–8.
Kenya National AIDS Control Council. Kenya HIV Estimates Report 2018. Nairobi, Kenya: Kenya Ministry of Health; 2018.
World Health Organization. Systematic Screening for Active Tuberculosis: Principles and Recommendations. Geneva, Switzerland: World Health Organization; 2013.
Kenyan Ministry of Health. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV in Kenya. Nairobi, Kenya: Kenyan Ministry of Health; 2018
Kenyan Ministry of Health. Guidelines for Management of Tuberculosis and Leprosy in Kenya. Nairobi, Kenya: Kenyan Ministry of Health; 2013.
LaCourse SM, Richardson BA, Kinuthia J, et al. A randomized controlled trial of isoniazid to prevent Mycobacterium tuberculosis infection in Kenyan HIV-exposed uninfected infants. Clinical Infect Dis. 2021;73:e337–e344.
Tuberculin reaction size on five consecutive days. Bull World Health Organ. 1955;12:189–196.
Cobelens F, Van Deutekom H, Draayer-Jansen I, et al. Tuberculin skin test reactions by time of reading among Dutch travellers. Int J Tuberc Lung Dis. 2003;7:758–763.
Impaact P1041: A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (Inh) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants with Perinatal Exposure to Hiv Trial Protocol [Protocol]. Available at: https://impaactnetwork.org/studies/P1041.asp . Accessed January 24, 2021.
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1–51.
Jonnalagadda S, Lohman Payne B, Brown E, et al. Latent tuberculosis detection by Interferon gamma release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children. J Infect Dis. 2010;202:1826–1835.
Teklu T, Legesse M, Medhin G, et al. Latent tuberculosis infection and associated risk indicators in pastoral communities in southern Ethiopia: a community based cross-sectional study. BMC Public Health. 2018;18:266.
Bekele A, Ashenafi S, Aderay G, et al. Latent tuberculosis among adult Ethiopian patients at chest clinic, Tikuranbessa specialized hospital, Addis Ababa, Ethiopia. Ethiop Med J. 2016;54:181–188.
Marquez C, Chamie G, Achan J, et al. Tuberculosis infection in early childhood and the association with hiv-exposure in hiv-uninfected children in rural Uganda. Pediatr Infect Dis J. 2016;35:524–529.
Almeida Santos J, Duarte R, Nunes C. Tuberculin skin test and predictive host factors for false-negative results in patients with pulmonary and extrapulmonary tuberculosis. Clin Respir J. 2020;14:541–548.
Pelly TF, Santillan CF, Gilman RH, et al. Tuberculosis skin testing, anergy and protein malnutrition in Peru. Int J Tuberc Lung Dis. 2005;9:977–984.
Petruccioli E, Chiacchio T, Navarra A, et al. Effect of hiv-infection on quantiferon-plus accuracy in patients with active tuberculosis and latent infection. J Infect. 2020;80:536–546.
Zifodya JS, LaCourse SM, Temu TM, Attia E, et al. Latent Tb Infection and Quantferon-Tb Gold Plus in Hiv-Infected and Uninfected Kenyan Adults. American Thoracic Society International Conference Abstracts. American Journal of Respiratory and Critical Care Medicine 2020;201:A2694.
Sutherland R, Yang H, Scriba TJ, et al. Impaired ifn-Γ-secreting capacity in mycobacterial antigen-specific Cd4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS. 2006;20:821–829.
Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating Cd4+ T-cells in hiv infection. Eur Respir J. 2010;35:619–626.
Johnson DF, Malone LL, Zalwango S, et al. Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection. PloS one. 2014;9:e96613.
O'Shea MK, Fletcher TE, Beeching NJ, et al. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants. PLoS One. 2014;9:e97366.
Jonnalagadda SR, Brown E, Lohman-Payne B, et al. Consistency of Mycobacterium tuberculosis-specific interferon-gamma responses in HIV-1-infected women during pregnancy and postpartum. Infect Dis Obstet Gynecol. 2012;2012:950650.
LaCourse SM, Wagner AD, Cranmer LM, et al. Brief report: high programmatic isoniazid preventive therapy (IPT) use in pregnancy among hiv-infected women. J Acquir Immune Defic Syndr. 2019;82:41–45.
Saha A, Escuduero J, Layouni T, et al. Mycobacterium tuberculosis-specific T cell responses are impaired during late pregnancy with elevated biomarkers of tuberculosis risk postpartum. medRxiv. 2021. doi: 10.06.11.21258789.
doi: 10.06.11.21258789
Theron G, Montepiedra G, Aaron L, et al. Individual and composite adverse pregnancy outcomes in a randomized trial on isoniazid preventative therapy among women living with hiv. Clinical Infect Dis. 2021;72:e784–e790.